Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
View Patent ↗Gene expression profiling reveals four distinct subgroups of multiple myeloma that have significant correlation with various clinical characteristics. Diagnosis for multiple myeloma (and possibly monoclonal gammopathy of undetermined significance) based on differential expression of 14 genes, as well as prognosis for the four subgroups of multiple myeloma based on the expression of 24 genes are established. A 15-gene model that classifies myeloma into 7 groups is also reported. Gene expression profiling also allows placing multiple myeloma into a developmental schema parallel to that of normal plasma cell differentiation. Development of a gene expression- or developmental stage-based classification system for multiple myeloma would lead to rational design of more accurate and sensitive diagnostics, prognostics and tumor-specific therapies for multiple myeloma.
1. A method of controlling bone loss in an individual having multiple myeloma comprising the step of inhibiting the expression of the DKK1 gene comprising SEQ I.D. NO:3 (GENBANK accession number NM — 012242).
2. The method of claim 1 , wherein said DKK1 gene expression is inhibited by anti-sense oligonucleotides or by anti-DKK1 antibodies.